Group 1: Earnings Performance - Potbelly reported quarterly earnings of $0.09 per share, exceeding the Zacks Consensus Estimate of $0.08 per share, and showing an increase from $0.08 per share a year ago, representing an earnings surprise of +12.50% [1] - The company posted revenues of $123.71 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.99%, and an increase from year-ago revenues of $119.7 million [2] Group 2: Stock Performance and Outlook - Potbelly shares have increased approximately 17.7% since the beginning of the year, outperforming the S&P 500's gain of 7.1% [3] - The current consensus EPS estimate for the upcoming quarter is $0.09 on revenues of $119.1 million, and for the current fiscal year, it is $0.23 on revenues of $476 million [7] Group 3: Industry Context - The Retail - Restaurants industry, to which Potbelly belongs, is currently ranked in the bottom 32% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - The performance of Potbelly's stock may be influenced by the overall outlook for the industry, as research indicates that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]

Company Performance - Niagen Bioscience (NAGE) reported quarterly earnings of $0.04 per share, exceeding the Zacks Consensus Estimate of $0.02 per share, compared to break-even earnings per share a year ago, representing an earnings surprise of +100.00% [1] - The company posted revenues of $31.12 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 8.99%, and showing an increase from year-ago revenues of $22.74 million [2] - Niagen Bioscience has consistently outperformed consensus EPS and revenue estimates over the last four quarters [2] Stock Performance - Niagen Bioscience shares have increased approximately 72.7% since the beginning of the year, significantly outperforming the S&P 500's gain of 7.1% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating it is expected to perform in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.03 on revenues of $30.95 million, and for the current fiscal year, it is $0.13 on revenues of $124.1 million [7] - The outlook for the Medical - Biomedical and Genetics industry, where Niagen Bioscience operates, is currently in the bottom 42% of over 250 Zacks industries, which may impact the stock's performance [8]

分组1 - Tandem Diabetes Care reported a quarterly loss of $0.48 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.4, and compared to a loss of $0.47 per share a year ago, indicating a surprise of -20.00% [1] - The company posted revenues of $240.68 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.87%, and showing an increase from year-ago revenues of $221.91 million [2] - The stock has underperformed significantly, losing about 57.9% since the beginning of the year, while the S&P 500 gained 7.1% [3] 分组2 - The current consensus EPS estimate for the coming quarter is -$0.26 on revenues of $253.39 million, and for the current fiscal year, it is -$1.36 on revenues of $1.01 billion [7] - The Zacks Industry Rank for Medical - Instruments is currently in the bottom 41% of over 250 Zacks industries, indicating potential challenges for stocks in this sector [8] - The estimate revisions trend for Tandem Diabetes Care was favorable ahead of the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, suggesting it is expected to outperform the market in the near future [6]

Company Performance - Keros Therapeutics reported a quarterly loss of $0.76 per share, which was better than the Zacks Consensus Estimate of a loss of $1.14, and an improvement from a loss of $1.25 per share a year ago, representing an earnings surprise of +33.33% [1] - The company posted revenues of $18.17 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 135.95%, compared to revenues of $0.04 million in the same quarter last year [2] - Over the last four quarters, Keros Therapeutics has surpassed consensus EPS estimates two times and topped consensus revenue estimates two times [2] Stock Performance - Keros Therapeutics shares have declined approximately 9.1% since the beginning of the year, while the S&P 500 has gained 7.1% [3] - The current consensus EPS estimate for the upcoming quarter is -$1.08 on revenues of $4.37 million, and for the current fiscal year, it is $0.21 on revenues of $219 million [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Keros Therapeutics belongs, is currently ranked in the bottom 42% of over 250 Zacks industries, indicating potential challenges ahead [8] - The performance of Keros Therapeutics may be influenced by the overall outlook of the industry, as research shows that the top 50% of Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1 [8]

Group 1: Earnings Performance - Aurora Cannabis Inc. reported a quarterly loss of $0.19 per share, compared to the Zacks Consensus Estimate of $0.18, and a loss of $0.11 per share a year ago, indicating an earnings surprise of -205.56% [1] - The company posted revenues of $75.49 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 6.50%, and compared to year-ago revenues of $67.27 million [2] - Over the last four quarters, Aurora Cannabis has surpassed consensus EPS estimates two times and topped consensus revenue estimates four times [2] Group 2: Stock Performance and Outlook - Aurora Cannabis shares have increased by approximately 8.2% since the beginning of the year, outperforming the S&P 500's gain of 7.1% [3] - The company's earnings outlook, including current consensus earnings expectations for upcoming quarters, will be crucial for investors [4] - The current consensus EPS estimate for the coming quarter is $0.09 on revenues of $65.3 million, and $0.56 on revenues of $272.14 million for the current fiscal year [7] Group 3: Industry Context - The Medical - Products industry, to which Aurora Cannabis belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact investor decisions [5]

Core Insights - NewAmsterdam Pharma Company N.V. reported a quarterly loss of $0.15 per share, significantly better than the Zacks Consensus Estimate of a loss of $0.52, representing an earnings surprise of +71.15% [1] - The company achieved revenues of $19.15 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 486.19%, compared to revenues of $2.28 million in the same quarter last year [2] - The stock has underperformed the market, losing about 15.5% since the beginning of the year, while the S&P 500 has gained 7.1% [3] Financial Performance - Over the last four quarters, NewAmsterdam Pharma has surpassed consensus EPS estimates two times and topped consensus revenue estimates four times [2] - The current consensus EPS estimate for the upcoming quarter is -$0.50 on revenues of $3.5 million, and for the current fiscal year, it is -$1.81 on revenues of $13.73 million [7] Market Outlook - The company's earnings outlook will be crucial for future stock performance, with management's commentary on the earnings call expected to influence investor sentiment [3][4] - The Zacks Rank for NewAmsterdam Pharma is currently 4 (Sell), indicating expectations of underperformance in the near future [6] - The Medical - Drugs industry, to which NewAmsterdam belongs, is currently in the top 34% of Zacks industries, suggesting a favorable industry outlook [8]

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. OppFi shares have added about 30.4% since the beginning of the year versus the S&P 500's gain of 7.1%. What's Next for OppFi? OppFi Inc. (OPFI) came out with quarterly earnings of $0.45 per share, beating the Zacks Consensus Estimate of $0.3 per share. This compares to earnings of $0.29 per share a year ago. The ...

Core Viewpoint - Ceragon Networks reported quarterly earnings of $0.03 per share, matching the Zacks Consensus Estimate, but down from $0.11 per share a year ago [1] - The company posted revenues of $82.26 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 8.01% and down from $96.09 million year-over-year [2] Financial Performance - Ceragon has surpassed consensus EPS estimates two times over the last four quarters [2] - The company has topped consensus revenue estimates three times in the last four quarters [2] - The current consensus EPS estimate for the upcoming quarter is $0.08 on revenues of $101.25 million, and for the current fiscal year, it is $0.25 on revenues of $389.1 million [7] Stock Performance - Ceragon shares have declined approximately 51.6% since the beginning of the year, contrasting with the S&P 500's gain of 7.1% [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating expected underperformance in the near future [6] Industry Outlook - The Wireless Non-US industry, to which Ceragon belongs, is currently in the top 32% of over 250 Zacks industries, suggesting a favorable industry outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Ceragon's stock performance [5]

Core Viewpoint - CDW reported quarterly earnings of $2.6 per share, exceeding the Zacks Consensus Estimate of $2.49 per share, and showing an increase from $2.5 per share a year ago, indicating a positive earnings surprise of +4.42% [1] Financial Performance - CDW's revenues for the quarter ended June 2025 were $5.98 billion, surpassing the Zacks Consensus Estimate by 8.51%, and up from $5.42 billion year-over-year [2] - Over the last four quarters, the company has exceeded consensus EPS estimates three times and topped revenue estimates three times [2] Stock Performance and Outlook - CDW shares have declined approximately 5.1% since the beginning of the year, while the S&P 500 has gained 7.1% [3] - The company's earnings outlook is crucial for assessing future stock performance, with current consensus EPS estimates at $2.62 for the coming quarter and $9.73 for the current fiscal year [7] Industry Context - The Computers - IT Services industry, to which CDW belongs, is currently ranked in the bottom 37% of over 250 Zacks industries, which may impact stock performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that monitoring these revisions can be beneficial for investors [5]

Core Viewpoint - LivaNova reported quarterly earnings of $1.05 per share, exceeding the Zacks Consensus Estimate of $0.84 per share, and showing an increase from $0.93 per share a year ago, indicating a strong earnings surprise of +25.00% [1][2] Financial Performance - The company achieved revenues of $352.5 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 6.56% and up from $318.6 million year-over-year [2] - Over the last four quarters, LivaNova has consistently surpassed consensus EPS estimates four times and topped revenue estimates three times [2] Stock Performance - LivaNova shares have declined approximately 8% since the beginning of the year, contrasting with the S&P 500's gain of 7.1% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.91 on revenues of $331.4 million, and for the current fiscal year, it is $3.65 on revenues of $1.32 billion [7] - The outlook for the Medical - Instruments industry, where LivaNova operates, is currently in the bottom 41% of Zacks industries, which may impact stock performance [8]